Evolocumab in STEMI

• Status: Recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to compare the size of myocardial infarct between evolocumab and control groups in patients with ST segment elevation myocardial infarction who undergoing primary percutaneous coronary intervention(PCI). All study participants will undergo a cardiac MRI 4 weeks after primary reperfusion. The evolocumab group will receive 420 mg before PCI via subcutaneous injection.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sejong General Hospital
• Collaborators: Catholic University of Korea Eunpyeong St. Mary's Hospital; Chonnam National University Hospital; Daegu Catholic University Medical Center; Inje University Ilsan Paik Hospital; National Health Insurance Service Ilsan Hospital; Samsung Medical Center
• Treatments: Evolocumab

Criteria

Inclusion Criteria:

• Typical ischemic chest pain persists for more than 30 minutes

• An elevation of an ST segment greater than 1 mm in two consecutive leads or new-onset left bundle branch block

• Presenting more than 12 hours after the onset of symptoms

Exclusion Criteria:

• Previous history of myocardial infarction

• Previous history of coronary bypass surgery

• Cardiogenic shock that lasts more than 10 minutes or cardiac arrest

• Occlusion of the left main coronary artery

• Pregnant or have a plan of pregnancy

• Serum creatinine level is >2.5mg/dL or dialysis is required